The block deal constituted 0.24% of the company's equity.
Meanwhile, the BSE Sensex was down 109.08 points, or 0.64%, to 17,025.47.
On BSE, 21.56 lakh shares were traded in the counter as against an average daily volume of 3.41 lakh shares in the past one quarter.
The stock hit a high of Rs 279.90 and a low of Rs 265 so far during the day. The stock had hit a 52-week high of Rs 295.30 on 10 August 2009 and a 52-week low of Rs 146.40 on 24 October 2008.
The large-cap stock underperformed the market over the past one month till 1 October 2009, rising 1.38% as compared to the Sensex's 10.18% rise. It had also underperformed the market in the past one quarter, gaining 11.04% as compared to the Sensex's return of 17%.
The company's equity capital is Rs 160.58 crore. Face value per share is Rs 2.
The current price of Rs 279.15 discounts the company's Q1 June 2009 annualized EPS of Rs 12.44, by a PE multiple of 22.44.
Late last month, the company issued and allotted 2.56 crore equity shares of Rs 2 each at Rs 263.75 per equity share (including a premium of Rs 261.75 per share) to qualified institutional bidders, thereby raising Rs 675.99 crore
Cipla's net profit surged 72.6% to Rs 241.71 crore on 13.2% rise in net sales to Rs 1325.26 crore in Q1 June 2009 over Q1 June 2008.
Cipla manufactures pharmaceutical products. The products of the company include anti-asthmatics, anti-cancer, anti-inflammatory, anti-depressant and other therapeutic index including animal health care products.